

MIDLANDS ENGINE HEALTH

Focus on Clinical Trials

Birmingham Clinical Research Facility

MIDLANDS
ENGINE



The National Institute for Health Research (NIHR) / Wellcome Trust Birmingham Clinical Research Facility (CRF) is an experimental medicine facility originally funded by the Wellcome Trust in 2001 as one of the founding and largest national facility of its kind. Today, it is now funded by the NIHR-funded CRFs in the Midlands.

The Birmingham CRF works collaboratively through Birmingham Health Partners, a strategic alliance of University Hospitals Birmingham NHS Foundation Trust, Birmingham Women's and Children's NHS Foundation Trust and the University of Birmingham. This partnership brings together clinical, scientific and academic excellence across an integrated medical and life sciences campus.

Year-on-year the CRF has expanded to offer new and innovative ways for patients to benefit from research and now includes:

- An adult and paediatric facility
- Adult and paediatric centres for rare diseases
- A facility focusing on inflammatory disease
- An advanced therapies facility
- A bio-resource centre allowing patients to take part in early phase, experimental and complex clinical research studies.

All adult facilities are based at the Queen Elizabeth Hospital, while paediatric services are delivered at Birmingham Children's Hospital.

In addition, the Birmingham CRF works with clinicians, academics and patients from many different specialties and offers outpatient, day-patient and inpatient accommodation, including a wide range of specialist investigation rooms and equipment.

All research conducted by the CRF is made possible by patient participation in clinical studies and the facility enables rich discussions to take place between researchers, patients and carers with lived experience of particular conditions.



Professor Elizabeth Sapey, Managing Director, Birmingham Clinical Research Facility

"The Birmingham CRF offers a purpose-designed clinical research space, highly trained and engaged staff and laboratory processing which ensures every trial we support is delivered to time, target and to the highest standards possible. The last year has been as busy as always for the CRF, and we are proud to report recruiting 12,457 participants into studies directly delivered with the CRF as well as supporting more than 1,000,000 regional participants in vaccine studies.

"Our work has included 25 first-in-man studies, delivering 33% of all the UK's advanced therapy studies and the building of new partnerships across academic and industry.

"This year offers even more opportunities to work with patients, researchers and companies to increase patient access to life-changing treatments."

